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Objectives:  Current  guidelines  tend  to  treat HIV  positive  (HIV+)  patients  as  their  seronegative  counter-
parts  with  diffuse  large  B-cell  lymphoma  (DLBCL)  but  little is known  about  their  radiotherapy  responses
differences.
Patients  and  Methods:  A  retrospective  cohort  of  all consecutive  HIV+  DBCL  patients  treated  with
chemotherapy  between  2004  and  2018  was  assessed.  All  patients  had  biopsy-proven  lymphomas.
They  were  included  if the proposed  radical treatment  was  done  without  progression  or  death  during
chemotherapy  and  had  at least  6 months  of  follow-up  or  were  followed  until  death.
Results:  Fifty-three  (53)  patients  were  selected,  with  a median  age  at diagnosis  of 41.39  years  (20–65
years).  Median  follow-up  of 35.16  months  (1.4–178.7  months).  Male  patients  accounted  for  54.7%  and
most  had  a good  performance  in the ECOG  scale  at diagnoses  (81.1%  are  ECOG  0−1).  Median  overall
survival  was  not  reached.  Mean  OS  was  41.5 months  with  16 deaths.  Age  had  an  impact  on  OS,  with
patients  older  than  60  years  at more  risk  (p = 0.044),  as  did longtime  use  of  HAART,  with  those  that
started  antiretroviral  therapy  within  the  diagnose  of the  lymphoma  at greatest  risk  (p =  0.044).  RT did
not  have  an  impact  on OS  (p  = 0.384)  or PFS  (p  =  0.420),  although  survival  curves  show  better  OS  in the
radiotherapy  group.  Toxicities  were  rare, since  none  of  the  patients  had  grade  3  or  superior  toxicity.
Conclusion:  RT  did  not  impact  survival  or  progression  in  our  limited  sample,  but  a longer  OS  may  occur
after  the  first-year  post  RT.  RT  should  be tested  in  prospective  data  in  the HIV+  population  with  DLBCL.








The role of radiotherapy (RT) in the treatment of non-Hodgkin
diffuse large B-cell lymphomas (DLBCL) has been tested over the
years. Prior to the development of rituximab, radiotherapy has been
a consistent option of consolidative therapy for initial disease over
the years. The GELA group1 trial that tried to compare an exten-
sive arm of chemotherapy (CHT) with insufficient CHT followed by
RT, concluded that RT cannot replace inadequate CHT regimens.
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s the randomization after the same schemes of CHT with com-
lete response between radiation or no longer treatment. In that
rial, RT showed an increase in disease-free survival (DSF). Follow-
ng the MabThera3 trial, radiation had yet again to prove its use. The
NFOLDER4 trial showed more results on the role of RT, especially
ecause the no-RT arms were prematurely closed due to improved
FS in the RT arm. Another issue altogether is the use of RT in the
dvanced disease setting. The International Lymphoma Radiation
ncology Group (ILROG) has proposed guidelines to its use in this
opulation.5 Nowadays, RT is an accepted option for consolidation
n DLBCL.
In the population of people living with HIV that are diagnosed
ith DLBCL, this information is particularly relevant, since for a long
ime the use of rituximab in this population has been avoided and
erved.
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Table 1
Patient characteristics and outcomes.








0 15 (60.0%) 20 (71.4%) 0.624
1 5 (20.0%) 3 (10.7%)
2  or lower 5 (20.0%) 5 (17.9%)
Staging
PET 5 (20.0%) 10 (35.7%) 0.093
CT 20 (80.0%) 18 (64.3%)
IPI
Low 4 (16.0%) 11 (39.3%) 0.135
Intermediate 10 (40.0%) 5 (17.8%)
High-intermediate 11 (44.0%) 11 (39.3%)
High 0 (0%) 1 (3.6%)
Stage
I  0 (0%) 4 (14.3%) 0.726
II 6 (24.0%) 8 (28.6%)
III 4 (16.0%) 3 (10.7%)
IV 15 (60.0%) 13 (46.4%)
Localization
Above diaphragm 6 (24.0%) 12 (42.9%) 0.957
Below diaphragm 4 (16.0%) 6 (21.4%)
Both sides 15 (60.0%) 10 (35.7%)
Bulky disease
No 19 (76.0%) 11 (39.3%) 0.468
Yes 6 (24.0%) 17 (60.7%)
Extranodal disease
No 15 (60.0%) 6 (21.4%) 0.233
Yes 10 (40.0%) 22 (78.6%)
B  Symptoms
No 18 (72.0%) 12 (42.9%) 0.279
Yes 7 (28.0%) 16 (57.1%)
HAART
No use 5 (20.0%) 2 (7.2%) 0.044
At lymphoma diagnosis 0 (0%) 5 (17.8%)
Long-term user 20 (80.0%) 20 (71.4%)
No information 0 (0%) 1 (3.6%)
Response to chemotherapy
Complete response 23 (92.0%) 17 (60.7%) 0.615
Partial response 2 (8.0%) 11 (39.3%)
Disease Progression
No 21(84.0%) 21 (75.0 %)
Yes 4 (16.0 %) 7 (25.0 %)
Death
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the impact of radiotherapy in this set is yet to be measured. Large
research groups have made recommendations for treatment in this
subset, such as the German AIDS Society (DAIG),6 but little evidence
is available and it is limited to small series,7 and little attention is
given to the role of radiotherapy.
Since it is a consolidative therapy, it is important to address the
correct indication and expected toxicities of RT in DLBCL patients.
It is a consensus that not every patient should receive RT and that
better knowledge of the disease and the effects of radiation is the
way that must be taken to improve patients’ outcomes.
An important, yet understudied, part of DLBCL patients are those
infected with the human immunodeficiency virus (HIV). An impor-
tant French prospective cohort has shown that survival among
patients living with HIV and that are diagnosed with DLBCL are
similar to HIV negative patients.8 In this cohort, nevertheless, radio-
therapy was not part of the treatment. Therefore, its use and
indications, as its toxicities, are unknown. This study aims to cast
some light on this issue.
2. Patients and methods
All consecutive patients that were diagnosed with DLBCL and
were people living with HIV virus treated with radiotherapy
between 2004 and 2018 were retrospectively assessed. Patients
that died before receiving any kind of treatment or died during
chemotherapy were not included. Previous evidence9 showed that
most patients had died during first course of chemotherapy. There-
fore, including those patients would be a bias since not all of them
received radiotherapy. Only patients that had reached the consoli-
dation phase of their treatment were included then. Patients with
only CNS disease who had received primary CNS lymphoma treat-
ments were also excluded. All patients had biopsy-proven DLBCL.
Patients had to have 6 months of follow up after the completion of
either RT or chemotherapy or were followed until death. Survival
(both OS and PFS) was assessed from the diagnosis date. Fifteen
patients (28.3%) were staged with Positron-emission tomography
with 18F-fluorodeoxyglucose (18F-FDG) and the others (71.7%) with
whole-body tomography (CT). Both methods were valid and their
use was also assessed in this population. All patients were also
assessed with the International Prognostic Index (IPI) and all were
re-classified by the current classification.10 Radiotherapy tech-
nique consisted of involved-field treatments for all patients treated
before 2015, which was changed after publication by Specht et al.11
and involved-site techniques were preferred. When available, PET-
CT images were used for delineation.
Statistical analyses were made with descriptive statistics and
frequencies analysis were conducted with calculation of means,
standard deviations (SD), medians and interquartile ranges (IQR).
Survival estimates were calculated using the Kaplan-Meier method
starting from diagnosis date and the log-rank test was  used for
comparisons between variables. All variables with clinical signif-
icance or p ≤ 0.10 in the univariate analysis were included in the
multivariate analysis. The Cox regression method was  used for the
multivariate analysis. Significance level was set at 5% (p < 0.05).
Ethics committee authorization was obtained in the local ethics
committee according to Brazilian law and the Declaration of
Helsinki. We  were granted a waiver by the ethics committee to
request each patient consent due to the retrospective nature of this
study.
3. ResultsPatients were retrospectively analyzed. Fifty-three patients
met  the inclusion criteria and had their data collected. All




957Yes 9 (36.0%) 7 (25.0%)
old value are significant value (p < 0.05).
as  41.39 years (interquartile range 34.90–48.20). 54.71% of the
atients were male. There was  one transgender female patient
n this sample. Most patients (81.12%) had performance grade
 or 1 in the ECOG scale. Most patients were not staged with
ositron-emission tomography with 18F-fluorodeoxyglucose (18F-
DG) (28.3%). Patients were graded according to the International
rognostic Index (IPI) and those with scores of 0 or 1 were a minor-
ty (28.3%), with most patients graded 3 (41.5%). Most patients were
lso advanced stage according to the Lugano system (66.0% were
tage III and IV). More information about patients’ characteristics
nd their impact on overall survival can be seen in Table 1.
HIV characteristics were also assessed. Median CD4+ cells
ount at diagnosis was 215 cells/mm3. Most patients had unde-
ectable viral loads, but 43.40% were with a median value of 221.5
opies/mL. Most patients (75.47%) were long time users of highly
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Table  2
HIV characteristics.








No use 5 (20.0%) 2 (7.2%) 0.044
At  lymphoma diagnosis 0 (0%) 5 (17.8%)
Long-term user 20 (80.0%) 20 (71.4%)
No information 0 (0%) 1 (3.6%)
NRTI in the current scheme
Yes 19 (76.0%) 4 (14.3%) 0.041
No  5 (20.0%) 23 (8.1%)
No  information 1 (4.0%) 1 (3.6%)
NNRTI in the current scheme
Yes 19 (76.0%) 17 (60.7%) 0.503
No  5 (20.0%) 10 (35.7%)
No information 1 (4.0%) 1 (3.6%)
Protease inhibitors in the current scheme
Yes 14 (56.0%) 15 (53.6%) 0.150
No  10 (40.0%) 12 (42.8%)
No  information 1 (4.0%) 1 (3.6%)
Integrase inhibitors in the current scheme
Yes 2 (8.0%) 5 (78.6%) 0.942
No  22 (88.0%) 22 (17.8%)
No  information 1 (4.0%) 1 (3.6%)
Fusion inhibitors in the current scheme
Yes 0 (0%) 0 (0%) –
No  24 (96.0%) 27 (96.4%)
No  information 1 (4.0%) 1 (3.6%)
CCR5 antagonist in the current scheme
Yes 0 (0%) 0 (0%) –
No  24 (96.0%) 27 (96.4%)
























patient received radiotherapy as a consolidation treatment. There-No  information 1 (4.0%) 1 (3.6%)
Bold values are significant values (p < 0.05).
active antiretroviral therapy (HAART), with impact on overall sur-
vival (p = 0.044) but no impact on disease progression (p = 0.261).
Long-term users had a statistically lower chance of dying after first-
line treatment for DLBCL. Seven patients (13.20%) were receiving
integrase inhibitors as dolutegravir at lymphoma diagnosis and
most patients were in use of older drug associations as their HAART
treatment. More data on HIV treatments for these patients and their
impact on overall survival can be seen in Table 2. An important tox-
icity outcome found was  the drop on the CD4+ cell count. Median
CD4+ cell count drop was 25.5 cells/mm3 (from an enhance of 269
to a drop of 370 cell/mm3 at diagnosis and at end of treatment) and
did not impact survival outcomes (p = 0.06).
Chemotherapy consisted mostly of protocols containing etopo-
side. No patient received rituximab in our sample and it is a
common practice in our institution to improve the common CHOP
regimen with the addition of etoposide (CHOEP) according to
older data for aggressive lymphomas12 (43.39% received etopo-
side containing regimens). Most patients received 6–8 cycles of
chemotherapy (45.28% and 43.39%, respectively). Response to
primary chemotherapy treatment was also assessed. Complete
response was acquired for 75.47% in their first line treatment.
Patients that progressed were excluded from analysis since they
would impact negatively the no-RT group and would create bias, so
the remaining patients reached partial response. Toxicities due to
chemotherapy were common, with 73.35% of patients having grade
3 or superior toxicities requiring pauses or treatment dose reduc-
tion and 28.30% having grade 4 hematological toxicity. All patients
with grade 5 toxicities were excluded from analysis.
Radiotherapy was standard when delivered. Twenty-eight




958Fig. 2. Progression-Free Survival (p = 0.420).
isted of involved site for 12 patients that were stage I or II and
reatment to bulky, extranodal or partial response sites to 16
atients with advanced stage disease. Standard dose was 30 or 30.6
y to complete response sites and 36 Gy to partial response sites.
2 patients were treated with the involved-field technique, most
efore 2015, and the remaining 31 were treated with the involved-
ite technique. RT was  included in multivariate analysis and did not
mpact any outcome. Consolidative radiotherapy did not impact the
utcome either (p = 0.33). Figs. 1 and 2 graphically describe the dif-
erence between patients that did and did not receive radiotherapy.
oxicities due to RT were rare and minor. Only 39.2% of patients had
ny grade 2 toxicities, mostly fatigue and skin alterations, with no
atients having grade 3 or higher toxicities.
Median follow-up was 35.16 months. Mean overall survival and
rogression-free survival for the entire cohort were 41.60 and 39.04
onths, respectively. No median values were reached. Univariate
nalysis and multivariate analysis on overall survival results can be
een in Table 3.
. Discussion
The association of HIV and DLBCL is a novel issue that lacks
ood quality data. The French cohort described by Besson et al.8
s the best evidence nowadays of this interaction. Although small,
t is good quality data acquired prospectively with current stan-
ards of the treatment of HIV infection. Regardless, the question
ddressed by these authors do not apply to most centers since noore, information on the way  people living with HIV deal with
oxicities and their prognoses is still absent in this treatment sce-
ario. Our study is the first one to our knowledge to address this
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Table  3
Univariate and multivariate analysis on overall survival.
Variable Categories Univariate analysis Multivariate analysis
n p p CI (95)
Gender Male 30 0.88 –
Female 23
Age <60 years 42 0.10 –
>60 years 11
ECOG 0−1  43 0.34 –
2−4 10
Staging exam PET-CT 15 0.13 –
CT 38








Localization Above diaphragm 18 0.63 –
Below diaphragm 10
Both sides 15
Bulky disease No 30 0.58 –
Yes 23
Extranodal disease No 21 0.22 –
Yes 32
B  Symptoms No 30 0.24 –
Yes 23
HAART No  use 7 0.04 0.10 −1.16 to 0.00
Started at diagnosis 5
Long-time user 40
No  information 1
Chemotherapy CHOP based 30 0.06 0.09 −2.12 to 0.14
Others 23

















Response to chemotherapy Complete 4
Partial 1
Bold values are significant values (p < 0.05).
issue. As it can be seen from our data, the most important inter-
action with HIV and the treatment for DLBCL is that people that
are receiving HAART at lymphoma diagnosis tend to do better.
This information is new and not reported previously. In the French
cohort, this information was mentioned as 79% of their patients
were receiving HAART at enrolment but no association was  made
between HIV treatment and outcomes.
Another question that must be addressed is that RT did not
interfere with the outcomes. The rationale of omitting RT in HIV
positive patients to make treatment less toxic is not true. In our
sample, no patient had enhanced toxicities due to RT. No sec-
ondary malignancies were reported. The impact of HIV on toxicities
from consolidative RT has been reported in a large sample of DLBL
patients13 but they are limited to increased fatigue and altered
blood cell count. The rationale, therefore, to omit RT based on HIV
status alone cannot be supported.
On the other hand, RT did not significantly impact survival.
This issue might be a consequence of the small sample size. It is
known from the pre and post MabThera radiotherapy trials that
the impact of RT on survival is limited and cannot be seen in small
patient groups. Nevertheless, the overall survival Kaplan-Meyer
curves showed can raise the question of whether RT can really
improve outcomes in this population. This subject should be, there-
fore, addressed by prospective trials.
5. ConclusionIn conclusion, patients living with HIV have similar outcomes
when treated with or without radiotherapy as consolidative treat-
ment after chemotherapy for DLBCL. Prospective data with larger
R
9590.68 –
amples are needed to really understand the impact of this treat-
ent in this special population.
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